Respiratory secretions near the end of life — Rapid

Synopsis

Distinguish expected upper-airway secretion from treatable pulmonary pathology, explain the sound without implying choking, use positioning and mouth care first, and prescribe an individual antimuscarinic trial only when likely benefit exceeds burden.

Terminal respiratory secretion usually reflects pooled saliva and airway fluid when swallowing and coughing diminish; it does not necessarily mean choking.
First-line assessment checks distress, consciousness, airway, oxygenation and whether onset or associated features suggest oedema, infection, aspiration, obstruction or blood.
Explain the mechanism and uncertainty to family before medicine: the sound often troubles listeners more than an unconscious patient.
First-line management is side positioning or head elevation, gentle mouth care and review of hydration, feeding, nebulisers and other contributors.
Avoid routine deep suction; remove only visible accessible material when it is likely to relieve obstruction and does not add distress.
Antimuscarinics reduce production of new fluid and work better when started before secretions are extensive; they cannot clear existing pooled fluid.
Choose one agent using local guidance, comorbidity and availability, then review sound, patient comfort, mouth dryness, urine retention and delirium.
The gold-standard outcome is patient comfort and informed family understanding, not complete silence at the cost of anticholinergic toxicity.
If the patient appears distressed, treat pain, breathlessness, pulmonary oedema or infection as relevant rather than escalating antimuscarinic solely for volume.

Key red flags

Stridor, choking, inability to ventilate or acute cyanosis requires airway emergency assessment rather than a routine secretion prescription.

Pink frothy sputum, new orthopnoea, widespread crackles or haemodynamic change suggests pulmonary oedema and possible diuretic or acute treatment.

Fresh haemoptysis, a sentinel bleed or known vessel erosion requires catastrophic-haemorrhage planning and urgent oncology or respiratory review.

Fever, purulent sputum, new hypoxaemia or focal signs suggests infection or aspiration pneumonia and should be treated according to goals.

Distress, grimacing or tachypnoea requires pain and breathlessness assessment; the sound alone does not reveal the patient's experience.

Deep suction causes discomfort, bleeding and more secretion and should not be used routinely in an unconscious dying person.

Antimuscarinics can cause urinary retention, dry mouth, blurred vision and delirium, with greater concern in frailty and renal impairment.

Central obstruction

Stridor, distress and reduced air entry suggest tumour, clot, foreign material or mucus plug needing urgent airway assessment.

Investigation priorities

First-line comfort and airway observationFirst stepFirst line

Assess consciousness, facial distress, breathing effort, airway patency, visible oral material, oxygenation and onset pattern.

Management branches

Typical secretionExplain, reposition and review fluid

A dying person develops gradual noisy upper-airway breathing without acute obstruction or visible distress.

Assess comfort and exclude sudden airway, bleeding, oedema or infection features and explain pooled secretion and swallowing change to family.
Reposition laterally or head up, provide mouth care and review whether fluid, feed, nebulisation or repeated suction is increasing burden.
If noise remains troubling, offer one individual antimuscarinic trial with a review time and monitor comfort, dry mouth, retention and delirium.

Key medicines

Glycopyrronium for terminal respiratory secretionGive 200 micrograms subcutaneously as needed, commonly every 4 hours under the local protocol, and use 600 to 1200 micrograms over 24 hours by continuous subcutaneous infusion when repeated doses help.It cannot remove existing fluid; monitor severe dry mouth, urinary retention, tachycardia and visual symptoms, and reduce or seek advice in renal impairment.

Hyoscine butylbromide for secretionA common palliative regimen is 20 mg subcutaneously as needed up to every 4 hours and 60 to 120 mg over 24 hours by continuous infusion when the local protocol selects it.Review urinary retention, glaucoma, tachyarrhythmia, bowel obstruction and dry mouth; check concentration-specific compatibility and do not combine routinely with another antimuscarinic.

Open full textbook →Answer 2 questions